Compare IAUX & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IAUX | ABCL |
|---|---|---|
| Founded | 2020 | 2012 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.6B |
| IPO Year | 2021 | 2020 |
| Metric | IAUX | ABCL |
|---|---|---|
| Price | $1.44 | $7.34 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $1.50 | ★ $8.40 |
| AVG Volume (30 Days) | ★ 10.1M | 6.5M |
| Earning Date | 05-12-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 11.76 | 10.91 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $95,193,000.00 | $75,128,000.00 |
| Revenue This Year | $132.25 | N/A |
| Revenue Next Year | $89.76 | $21.85 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 89.12 | ★ 160.56 |
| 52 Week Low | $0.55 | $2.75 |
| 52 Week High | $2.24 | $6.86 |
| Indicator | IAUX | ABCL |
|---|---|---|
| Relative Strength Index (RSI) | 43.54 | 70.75 |
| Support Level | $0.92 | $3.32 |
| Resistance Level | $1.65 | N/A |
| Average True Range (ATR) | 0.07 | 0.49 |
| MACD | -0.01 | 0.11 |
| Stochastic Oscillator | 23.08 | 87.27 |
i-80 Gold Corp is a well-financed gold and silver producer engaged in the exploration, development, and production of gold, silver, and poly-metallic deposits. The Company's principal assets include the Ruby Hill Mine, Lone Tree Mine, Granite Creek Mine, and McCoy-Cove Project.
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.